HighVista Strategies LLC Sells 17,154 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

HighVista Strategies LLC reduced its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 21.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 61,788 shares of the company’s stock after selling 17,154 shares during the quarter. Apogee Therapeutics accounts for about 1.3% of HighVista Strategies LLC’s holdings, making the stock its 19th biggest holding. HighVista Strategies LLC owned approximately 0.14% of Apogee Therapeutics worth $3,629,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of APGE. Driehaus Capital Management LLC boosted its position in Apogee Therapeutics by 2.6% in the second quarter. Driehaus Capital Management LLC now owns 2,117,870 shares of the company’s stock valued at $83,338,000 after buying an additional 54,107 shares in the last quarter. Perceptive Advisors LLC grew its position in Apogee Therapeutics by 2.2% during the 2nd quarter. Perceptive Advisors LLC now owns 2,105,636 shares of the company’s stock worth $82,857,000 after acquiring an additional 45,241 shares during the last quarter. Affinity Asset Advisors LLC increased its holdings in Apogee Therapeutics by 41.2% in the 2nd quarter. Affinity Asset Advisors LLC now owns 836,283 shares of the company’s stock worth $32,908,000 after purchasing an additional 244,190 shares in the last quarter. Waypoint Capital Advisors LLC bought a new position in Apogee Therapeutics in the third quarter valued at about $36,835,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Apogee Therapeutics by 121.6% during the third quarter. Victory Capital Management Inc. now owns 346,358 shares of the company’s stock valued at $20,345,000 after purchasing an additional 190,092 shares in the last quarter. 79.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on APGE. Wedbush upped their price objective on Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday. Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Finally, Guggenheim lifted their target price on Apogee Therapeutics from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, November 27th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics currently has an average rating of “Buy” and a consensus price target of $83.88.

Apogee Therapeutics Stock Up 2.2 %

APGE stock opened at $46.14 on Tuesday. The company’s fifty day simple moving average is $53.40 and its 200 day simple moving average is $48.39. Apogee Therapeutics, Inc. has a 12-month low of $18.84 and a 12-month high of $72.29. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -19.14 and a beta of 2.93.

Insider Transactions at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00. Following the transaction, the chief executive officer now owns 1,339,487 shares in the company, valued at $79,324,420.14. The trade was a 1.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Carl Dambkowski sold 6,665 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $47.56, for a total transaction of $316,987.40. Following the completion of the sale, the insider now owns 280,793 shares of the company’s stock, valued at $13,354,515.08. The trade was a 2.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,995 shares of company stock valued at $6,128,295. Corporate insiders own 36.10% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.